Press Releases

Month Year

Get News Alerts by Email

Dec 7, 2018

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

Eisai announced today that the first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is to enter Phase I clinical trials for Alzheimer's...
Dec 4, 2018

New Analyses Evaluate Long-Term Convulsive Seizure Freedom Rates With Use Of Adjunctive FYCOMPA® (perampanel) CIII In Adult Patients Presented at Annual Meeting of the American Epilepsy Society (AES)

-- In a real-world, observational, retrospective study of FYCOMPA as a first add-on therapy, 61% (19/31) of patients with generalized seizures achieved seizure freedom, with an overall retention rate of 85% (127/149) at 12 months

Eisai Inc. presented new data on FYCOMPA® (perampanel) CIII at the American Epilepsy Society Annual Meeting in New Orleans which included analyses of convulsive seizure freedom rates in adult and...
Nov 21, 2018

Eisai To Present FYCOMPA Long-Term Sustained Seizure Freedom And Pediatric Data At Upcoming American Epilepsy Society Annual Meeting

Eisai Inc. today announced that it will present FYCOMPA® (perampanel) CIII long-term seizure freedom and pediatric data at the upcoming American Epilepsy Society Annual Meeting taking place from...
- Photos 1
Oct 25, 2018

Eisai and Biogen Announce Presentation of Additional Data from the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”)...
Oct 24, 2018

Eisai and Oklahoma Health Care Authority Enter Value-Based Agreement for FYCOMPA

Eisai Inc. the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that they have signed a value-based contract for FYCOMPA® (perampanel) CIII with Oklahoma Health Care Authority...
Oct 17, 2018

Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At The 11th Clinical Trials On Alzheimer's Disease (CTAD) Conference

Additional Data from BAN2401 Phase 2 Results to be Presented

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that five oral and two poster presentations from its Alzheimer's disease pipeline, including additional data on...
Oct 17, 2018

Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant

Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy objectives

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced positive topline results from SUNRISE 2, a long-term Phase...
Oct 16, 2018

Eisai To Present New Research On Human Genetics And Drug Discovery At ASHG Conference 2018

Five scientific presentations and a video profiling new Eisai Center in Cambridge, Massachusetts to be presented at conference

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 5 poster presentations reporting new research on human genetics guided drug discovery will be highlighted at...
Oct 4, 2018

Eisai Announces New Data on the Effect of Anti-Obesity Agent BELVIQ® (lorcaserin HCl) on Prevention and Remission of Type 2 Diabetes Presented at the European Association for the Study of Diabetes (EASD) and Published in The Lancet

- In secondary metabolic analyses of CAMELLIA-TIMI 61, patients with pre-diabetes who were treated with BELVIQ were less likely to develop diabetes and had a greater tendency to achieve normal blood glucose levels compared to patients treated with placebo

Eisai Inc. announced today new data on prevention and remission of diabetes from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with anti-obesity agent BELVIQ®...
- Photos 1
Sep 28, 2018

Eisai Announces FDA Approval Of FYCOMPA® in Pediatric Patients As Young As 4 Years Old For The Treatment Of Partial-Onset Seizures

- FYCOMPA is an important new option for pediatric patients to potentially improve seizure control

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug FYCOMPA® (perampanel) CIII for monotherapy and adjunctive use in...
Aug 27, 2018

Eisai Announces Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ® Presented at the European Society of Cardiology and Published in the New England Journal of Medicine

- CAMELLIA-TIMI 61 is first large-scale outcomes trial to achieve long-term cardiovascular (CV) safety for a weight loss agent

Eisai Inc. announced today that results from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily were presented at the...
Jul 25, 2018

Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
Jul 25, 2018

Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
Jul 18, 2018

Eisai To Present Latest Data On Alzheimer's Disease / Dementia Pipeline At Alzheimer's Association International Conference 2018

Thirteen presentations to be given including late breaking Phase 2 study results of BAN2401 and elenbecestat

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 13 posters and presentations from its robust Alzheimer's disease pipeline, including the Phase 2 clinical...
Jul 17, 2018

Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®

- BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients

Eisai Inc. announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial. This 12,000 patient study of BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily was conducted at...
Jul 9, 2018

Eisai Announces Acceptance of BAN2401 Phase II Results for Oral Presentation at the 2018 Alzheimer's Association International Conference (AAIC)

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today the results of the BAN2401 Phase II clinical study, Study 201(ClinicalTrials.gov identifier NCT01767311), will be...
Jul 5, 2018

Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months

- The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
Jul 2, 2018

Eisai and Purdue Pharma Announce Oral Presentation of Latest Clinical and Non-Clinical Data on Lemborexant at 43rd Annual Meeting of the Japanese Society of Sleep Research

Presentation includes data from first-ever Phase 3 head-to-head superiority comparison vs zolpidem ER in patients with a sleep-wake disorder

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced that they will present data on their investigational...
Jun 5, 2018

Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting

Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their...
Jun 5, 2018

Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months

RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
May 30, 2018

Eisai Receives FDA Priority Review Designation for FYCOMPA® (perampanel) CIII Pediatric Indications Supplemental New Drug Application (sNDA)

- Designation underscores the need to expand potential treatment options to help certain young patients achieve goal of seizure freedom

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for its antiepileptic drug FYCOMPA®...
May 22, 2018

Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting

Companies will present data on: Postural stability after middle-of-the-night awakening and next-morning compared to zolpidem ER Auditory awakening threshold Return to sleep latency compared to...
Apr 19, 2018

Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA

Abstracts presented add to growing body of FYCOMPA data supporting convulsive seizure freedom, and real-world, long-term safety & efficacy data

Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include...
Mar 30, 2018

Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA® (perampanel) Pediatric Indications

- First step to making FYCOMPA available for children, underscoring Eisai's commitment to epilepsy care for patients of all ages

Eisai Inc. announced today that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for its antiepileptic drug FYCOMPA®...
Mar 7, 2018

Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant Including First-Ever Phase 3 Head-to-Head Superiority Comparison Versus Zolpidem ER in Patients With Sleep Disorder

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant,...

Show per page

Open a printable version of this page
Email the URL of this page to a friend